APA (7th ed.) Citation

Connick, P., Kolappan, M., Patani, R., Scott, M. A., Crawley, C., He, X., . . . Chandran, S. (2011). The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: An open-label pre-test: post-test study with blinded outcome assessments. Current controlled trials in cardiovascular medicine, 12(1), 62. https://doi.org/10.1186/1745-6215-12-62

Chicago Style (17th ed.) Citation

Connick, Peter, et al. "The Mesenchymal Stem Cells in Multiple Sclerosis (MSCIMS) Trial Protocol and Baseline Cohort Characteristics: An Open-label Pre-test: Post-test Study with Blinded Outcome Assessments." Current Controlled Trials in Cardiovascular Medicine 12, no. 1 (2011): 62. https://doi.org/10.1186/1745-6215-12-62.

MLA (9th ed.) Citation

Connick, Peter, et al. "The Mesenchymal Stem Cells in Multiple Sclerosis (MSCIMS) Trial Protocol and Baseline Cohort Characteristics: An Open-label Pre-test: Post-test Study with Blinded Outcome Assessments." Current Controlled Trials in Cardiovascular Medicine, vol. 12, no. 1, 2011, p. 62, https://doi.org/10.1186/1745-6215-12-62.